Physician profile
Michael F Pingree
NPI 1982716031
$2,518.43
in general payments reported to CMS, 2019-2025
16 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $236 · 2021: $340 · 2022: $405 · 2023: $348 · 2024: $339 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $686.19 | 2019-2025 | Clareon, Argos, Precision 1 |
| Bausch & Lomb Americas INC. | $361.33 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $251.11 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $247.73 | 2019-2025 | Cequa, Xelpros |
| Coopervision INC. | $195.43 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Glaukos Corporation | $186.82 | 2019-2025 | Idose, Idosetr, Photrexa Viscous and Photrexa |
| Novartis Pharmaceuticals Corporation | $143.08 | 2020-2023 | |
| Allergan, INC. | $118.73 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $85.49 | 2019-2021 | |
| Abbvie INC. | $53.03 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $39.61 | 2021-2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $38.44 | 2025 | Lipiflow System Activator (Disposable) |
| Tarsus Pharmaceuticals, INC. | $32.56 | 2025 | Xdemvy |
| Shire North American Group INC | $22.15 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $17.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pingree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.